Nyxoah SA (NASDAQ:NYXH) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Nyxoah SA (NASDAQ:NYXH) have received an average recommendation of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $11.6667.

Several brokerages have recently commented on NYXH. Weiss Ratings restated a “sell (d-)” rating on shares of Nyxoah in a research report on Monday, December 29th. Stifel Nicolaus decreased their target price on Nyxoah from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, January 29th. Cantor Fitzgerald raised Nyxoah to a “strong-buy” rating in a report on Wednesday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $9.00 price objective (down from $12.00) on shares of Nyxoah in a report on Friday, November 14th.

Nyxoah Trading Down 2.3%

Shares of Nyxoah stock opened at $3.85 on Thursday. The company has a market capitalization of $131.10 million, a P/E ratio of -1.55 and a beta of 1.56. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.41 and a current ratio of 1.70. The company has a fifty day moving average of $4.67 and a 200 day moving average of $5.08. Nyxoah has a fifty-two week low of $3.74 and a fifty-two week high of $11.87.

Institutional Trading of Nyxoah

A number of institutional investors and hedge funds have recently bought and sold shares of NYXH. Raymond James Financial Inc. increased its stake in Nyxoah by 35.6% during the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after acquiring an additional 3,353 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Nyxoah by 72.4% in the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after purchasing an additional 3,303 shares during the period. Citadel Advisors LLC bought a new position in shares of Nyxoah during the 3rd quarter valued at approximately $98,000. Deutsche Bank AG increased its position in shares of Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Shay Capital LLC purchased a new stake in Nyxoah during the 2nd quarter valued at $374,000.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.